Choosing the right combination therapy in severe community-acquired pneumonia

Critical Care

Volumn 10, Issue 1, 2006, Pages

  Waterer, Grant W ^a   Rello, Jordi ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CYTOKINE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; HEALTH CARE QUALITY; HOSPITAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INTUBATION; LOBAR PNEUMONIA; MORTALITY; NOTE; PATIENT CARE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RISK REDUCTION; SEPSIS; COMMUNICABLE DISEASE; DRUG COMBINATION; MICROBIOLOGY; PNEUMONIA; REVIEW;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA;

EID: 33745478885     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc3976     Document Type: Note

References (20)

1. Mufson MA Stanek RJ Bacteremic pneumococcal pneumonia in one American City: A 20-year longitudinal study, 1978-1997 Am J Med 1999 107 34S-43S 10.1016/S0002-9343(99)00098-4 10451007
2. Waterer GW Somes GW Wunderink RG Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia Arch Intern Med 2001 161 1837-1842 10.1001/archinte.161.15.1837 11493124
3. Martinez JA Horcajada JP Almela M Marco F Soriano A Garcia E Marco MA Torres A Mensa J Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia Clin Infect Dis 2003 36 389-395 10.1086/367541 12567294
4. Baddour LM Yu VL Klugman KP Feldman C Ortqvist A Rello J Morris AJ Luna CM Snydman DR Ko WC Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia Am J Respir Crit Care Med 2004 170 440-444 10.1164/rccm.200311-1578OC 15184200
5. Weiss K Low DE Cortes L Beaupre A Gauthier R Gregoire P Legare M Nepveu F Thibert D Tremblay C Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults Can Respir J 2004 11 589-593 15611810
6. Dudas V Hopefl A Jacobs R Guglielmo BJ Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: A survey of nonteaching US community hospitals Ann Pharmacother 2000 34 446-452 10.1345/aph.19174 10772428
7. Brown RB Iannini P Gross P Kunkel M Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: Analysis of a hospital claims-made database Chest 2003 123 1503-1511 10.1378/ chest.123.5.1503 12740267
8. Houck PM MacLehose RF Niederman MS Lowery JK Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1995, and 1997 Chest 2001 119 1420-1426 10.1378/chest.119.5.1420 11348948
9. Garcia Vazquez E Mensa J Martinez JA Marcos MA Puig J Ortega M Torres A Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone Eur J Clin Microbiol Infect Dis 2005 24 190-195 10.1007/ s10096-005-1295-9 15782278
10. Mortensen EM Restrepo MI Anzueto A Pugh J The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia Crit Care 2006 10 R8 16469131 10.1186/cc3934
11. Lagrou K Peetermans WE Jorissen M Verhaegen J Van Damme J Van Eldere J Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro J Antimicrob Chemother 2000 46 717-723 10.1093/jac/46.5.717 11062190
12. Parnham MJ Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections Curr Opin Infect Dis 2005 18 125-131 10.1097/01.qco.0000160901.71813.fe 15735416
13. Sabria M Pedro-Botet ML Gomez J Roig J Vilaseca B Sopena N Banos V Fluoroquinolones vs macrolides in the treatment of Legionnaires disease Chest 2005 128 1401-1405 10.1378/chest.128.3.1401 16162735
14. Williams AC Galley HF Watt AM Webster NR Differential effects of three antibiotics on T helper cell cytokine expression J Antimicrob Chemother 2005 56 502-506 10.1093/jac/dki251 16006447
15. Culic O Erakovic V Cepelak I Barisic K Brajsa K Ferencic Z Galovic R Glojnaric I Manojlovic Z Munic V Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects Eur J Pharmacol 2002 450 277-289 10.1016/S0014-2999(02)02042-3 12208321
16. Shinkay M Park CS Rubin BK Immunomodulatory effects of macrolide antibiotics Clin Pulm Med 2005 12 341-348 10.1097/ 01.cpm.0000187294.53696.c0
17. Dalhoff A Shalit I Immunomodulatory effects of quinolones Lancet Infect Dis 2003 3 359-371 10.1016/S1473-3099(03)00658-3 12781508
18. Rello J Diaz E Bodi M Catalan M Alvarez B Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia Intensive Care Med 2003 28 1030-1035
19. Gleason PP Meehan TP Fine JM Galusha DH Fine MJ Associations between initial antimicrobial therapy and medical outcomes for hospitalized patients with pneumonia Arch Intern Med 1999 159 2562-2572 10.1001/ archinte.159.21.2562 10573046
20. Bodi M Rodriguez A Sole-Violan J Gilavert MC Garnacho J Blanquer J Jimenez J de la Torre MV Sirvent JM Almirall J Antibiotic prescribing for community-acquired pneumonia in the intensive care unit: Impact of adherence to Infectious Diseases Society of America Guidelines on survival Clin Infect Dis 2005 41 1709-1716 10.1086/498119 16288392